18F-PSMA-1007多参数动态PET/CT在前列腺癌生化复发与进展中的研究
该研究纳入25例前列腺癌生化复发或进展患者,采用18F-PSMA-1007动态及全身PET/CT评估其生物分布与药代动力学。15/25例PET阳性,阳性组PSA中位值3.6 ng/mL高于阴性组0.7 ng/mL。动态PET显示病灶内示踪剂摄取随时间递增,且SUV、流入率与分形维数显著相关。
要点
- 18F-PSMA-1007 PET/CT在混合人群中检出60%前列腺癌病灶。
- PSA越高,18F-PSMA-1007 PET/CT检出率越高。
- 动态PET显示病灶内示踪剂摄取60分钟内持续增加。
核心结论
- 18F-PSMA-1007 PET/CT可在60%的混合前列腺癌患者中检出病灶,包括PSA极低者。
- 较高PSA值与较高检出率相关。
- 动态PET分析显示病灶内示踪剂摄取递增,提示放射性氟化PSMA配体在前列腺癌病灶中高结合与内化。
研究设计与样本
- 研究纳入25例前列腺癌生化复发或进展患者,中位年龄66.0岁。
- 中位PSA值为1.2 ng/mL(范围0.1-237.3 ng/mL),中位Gleason评分为7(范围6-10)。
- 所有患者接受盆腔及下腹部60分钟动态PET/CT和全身18F-PSMA-1007 PET/CT。
- PET/CT评估基于定性评价、SUV计算以及基于两组织室模型和分形分析的定量分析。
主要发现
- 15/25例患者PET阳性。
- 18F-PSMA-1007阳性组血浆PSA中位值3.6 ng/mL(范围0.2-237.3 ng/mL),阴性组中位值0.7 ng/mL(范围0.1-3.0 ng/mL)。
- 前列腺癌病灶半定量分析显示平均SUVaverage=25.1(中位15.4;范围3.5-119.2),平均SUVmax=41.5(中位25.7;范围3.8-213.2)。
- 动态PET/CT的时间-活度曲线显示60分钟采集期间病灶内示踪剂累积持续增加,高于膀胱和结肠。
- 18F-PSMA-1007摄取(SUV)、流入率和分形维数(FD)之间观察到显著相关性。
临床怎么用
- 18F-PSMA-1007 PET/CT可用于前列腺癌生化复发或进展患者的病灶检出,尤其适用于PSA值较低的患者。
- 动态PET参数(如流入率、分形维数)与SUV相关,可能为病灶表征提供补充信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Aim of the present analysis is to investigate the biodistribution and pharmacokinetics of the recently clinically introduced radioligand 18F-PSMA-1007 in patients with biochemical recurrence or progression of prostate cancer (PC) by means of multiparametric (dynamic and whole-body) PET/CT. METHODS: Twenty-five (25) patients with PC biochemical relapse or progression (median age = 66.0 years) were enrolled in the analysis. The median PSA value was 1.2 ng/mL (range = 0.1-237.3 ng/mL) and the median Gleason score was 7 (range = 6-10). All patients underwent dynamic PET/CT (dPET/CT) scanning (60 min) of the pelvis and lower abdomen as well as whole-body PET/CT with 18F-PSMA-1007. PET/CT assessment was based on qualitative evaluation, SUV calculation, and quantitative analysis based on a two-tissue compartment model and fractal analysis. RESULTS: 15/25 patients were PET-positive. Plasma PSA values in the 18F-PSMA-1007 positive group were higher (median = 3.6 ng/mL; range = 0.2-237.3 ng/mL) than in the 18F-PSMA-1007 negative group (median value = 0.7 ng/mL; range = 0.1-3.0 ng/mL). Semi-quantitative analysis in the PC lesions demonstrated a mean SUVaverage = 25.1 (median = 15.4; range = 3.5-119.2) and a mean SUVmax = 41.5 (median = 25.7; range = 3.8-213.2). Time-activity curves derived from dPET/CT revealed an increasing tracer accumulation during the 60 min of dynamic PET acquisition into the PC lesions, higher than in the urinary bladder and the colon. Significant correlations were observed between 18F-PSMA-1007 uptake (SUV), influx, and fractal dimension (FD). CONCLUSIONS: 18F-PSMA-1007 PET/CT could detect PC lesions in 60% of the patients of a mixed population, including also patients with very low PSA values. Higher PSA values were associated with a higher detection rate. Dynamic PET analysis revealed an increasing tracer uptake during the dynamic PET acquisition as well as high binding and internalization of the radiofluorinated PSMA ligand in the PC lesions.
引用
- Sachpekidis C, Afshar-Oromieh A, Kopka K, et al. 18F-PSMA-1007 multiparametric, dynamic PET/CT in biochemical relapse and progression of prostate cancer. Eur J Nucl Med Mol Imaging. 2019. PMID: 31728588. doi:10.1007/s00259-019-04569-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。